Business, energy, technology, markets and global industry news from Business News Today

CAN-004

PharmaDeviceNews CAN-004
PleoPharma’s $6.5 million NIDA grant supports the Phase 3 CAN-004 trial of investigational PP-01 for cannabis withdrawal in adults with cannabis use disorder, putting the 420-patient study at the centre of the company’s late-stage development strategy. Representative image.
Pharma & Biotech

Can PP-01 become the first approved cannabis withdrawal treatment? PleoPharma’s Phase 3 test begins

PleoPharma secures $6.5M NIDA funding as a 420-patient Phase 3 trial tests PP-01 for cannabis withdrawal in adults with cannabis use disorder.

Read More